Trial Profile
A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to Lantus in Adult Chinese Patients With Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 01 Jun 2022 Results published in the Diabetes, Obesity and Metabolism
- 01 Aug 2021 Primary endpoint has been met (Change from Baseline in Hemoglobin A1c (HbA1c) (LY2963016 Noninferior to Lantus)) , according to Results published in the Diabetes, Obesity and Metabolism
- 01 Aug 2021 Results published in the Diabetes, Obesity and Metabolism